Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
The chart shows the growth of an initial investment of $10,000 in Quanterix Corporation Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Quanterix Corporation Common Stock (QTRX) has returned -40.31% so far this year and -32.44% over the past 12 months. Looking at the last ten years, QTRX has achieved an annualized return of -13.55%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Quanterix Corporation Common Stock (QTRX) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.16% | 3.80% | -43.86% | 6.16% | ||||||||
| 2025 | -15.38% | -15.48% | -18.42% | -15.29% | -9.88% | 27.88% | -10.14% | -21.55% | 20.67% | -0.56% | 35.96% | -12.03% |
| 2024 | -17.91% | 5.97% | 2.70% | -31.40% | -0.44% | -18.91% | 11.56% | -11.66% | 2.13% | 2.60% | -7.92% | -13.72% |
| 2023 | 0.07% | -22.43% | 2.92% | 13.06% | 55.63% | 14.76% | 10.89% | 8.81% | 0.78% | -21.45% | 10.77% | 15.31% |
| 2022 | -28.99% | 10.26% | -13.69% | -24.32% | -23.29% | -4.54% | -1.78% | -41.45% | 19.78% | -0.45% | 17.18% | 4.45% |
| 2021 | 37.31% | 15.49% | -23.74% | 0.07% | -16.09% | 13.90% | -8.57% | -4.78% | -2.77% | 2.24% | -21.04% | 3.41% |
| 2020 | 13.57% | -16.99% | -19.64% | 48.02% | 6.53% | 0.11% | 17.62% | 7.85% | -4.61% | 7.80% | 16.73% | 7.39% |
| 2019 | 15.65% | 16.78% | 3.94% | -12.04% | 11.64% | 32.72% | -9.49% | -15.50% | -15.70% | -4.27% | 20.79% | -5.78% |
| 2018 | -3.34% | 3.62% | -17.26% | -0.12% | 9.30% | -22.21% | 3.59% | 11.53% | 28.11% | -19.09% | 6.36% | -3.83% |
| 2017 | 32.12% |
The charts below present risk-adjusted performance metrics for Quanterix Corporation Common Stock (QTRX) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of QTRX compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Quanterix Corporation Common Stock volatility is 4.09%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 418.77M | 406.53M | 425.01M | 434.20M | 501.53M | 271.05M | 169.95M | 67.61M |
| Equity Attributable To Parent (USD) | 295.73M | 330.04M | 346.93M | 358.94M | 440.95M | 206.13M | 128.66M | 41.07M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - |
| Equity (USD) | 295.73M | 330.04M | 346.93M | 358.94M | 440.95M | 206.13M | 128.66M | 41.07M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | 17.43M | 13.77M | 658.00K |
| Long-term Debt (USD) | - | - | - | - | - | 7.69M | 7.69M | 7.76M |
| Noncurrent Liabilities (USD) | 48.27M | 34.49M | 39.63M | 44.30M | 23.60M | 25.12M | 21.46M | 8.42M |
| Other Current Liabilities (USD) | 61.19M | 35.05M | 33.41M | 27.12M | 27.77M | 33.00M | 14.06M | 13.02M |
| Accounts Payable (USD) | 13.57M | 6.95M | 5.05M | 3.84M | 9.21M | 6.80M | 5.78M | 5.11M |
| Current Liabilities (USD) | 74.76M | 42.01M | 38.46M | 30.96M | 36.98M | 39.80M | 19.83M | 18.13M |
| Liabilities (USD) | 123.04M | 76.50M | 78.08M | 75.26M | 60.58M | 64.92M | 41.29M | 26.55M |
| Other Non-current Assets (USD) | 51.05M | 21.76M | 22.66M | 25.12M | 24.08M | 23.81M | 10.94M | 2.84M |
| Intangible Assets (USD) | 131.79M | 4.03M | 6.03M | 7.52M | 10.53M | 13.72M | 14.31M | 2.35M |
| Fixed Assets (USD) | 23.67M | 17.15M | 17.93M | 20.16M | 17.96M | 13.91M | 12.05M | 2.92M |
| Noncurrent Assets (USD) | 206.51M | 42.94M | 46.62M | 52.80M | 52.57M | 51.44M | 37.29M | 8.12M |
| Other Current Assets (USD) | 157.49M | 330.82M | 356.03M | 364.62M | 426.77M | 204.75M | 122.20M | 53.55M |
| Inventory (USD) | 54.76M | 32.78M | 22.37M | 16.79M | 22.19M | 14.86M | 10.46M | 5.95M |
| Current Assets (USD) | 212.26M | 363.59M | 378.39M | 381.40M | 448.96M | 219.61M | 132.66M | 59.50M |
| Assets (USD) | 418.77M | 406.53M | 425.01M | 434.20M | 501.53M | 271.05M | 169.95M | 67.61M |
The article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.
Monteverde & Associates PC, a class action law firm, is investigating several proposed mergers, including Akoya Biosciences' merger with Quanterix, Welsbach Technology Metals Acquisition's merger with Evolution Metals LLC, and Playa Hotels & Resorts' merger with Hyatt Hotels Corporation.
The M&A Class Action Firm is investigating proposed mergers involving Paragon 28, Inc. (FNA), Beacon Roofing Supply, Inc. (BECN), Quanterix Corporation (QTRX), and Playa Hotels & Resorts N.V. (PLYA), urging shareholders to take action.
Quanterix Corporation (NASDAQ: QTRX) announced that its previously issued financial statements should no longer be relied upon, causing its stock price to drop 18.3%. The Rosen Law Firm is investigating potential securities claims on behalf of shareholders.
The M&A Class Action Firm is investigating the proposed mergers of Evergreen Corporation, Quanterix Corporation, Arcadia Biosciences, and Enterprise Bancorp, providing information for shareholders.
Quanterix Corporation (NASDAQ: QTRX) announced that its previously issued financial statements should no longer be relied upon, causing its stock price to drop 18.3%. The Rosen Law Firm is investigating potential securities claims on behalf of Quanterix shareholders.
Quanterix Corporation (NASDAQ: QTRX) announced that its previously issued financial statements should no longer be relied upon, causing its stock price to drop 18.3%. The Rosen Law Firm is investigating potential securities claims on behalf of shareholders.
Quanterix Corporation (NASDAQ: QTRX) announced that its previously issued financial statements should no longer be relied upon, causing its stock price to drop 18.3%. The Rosen Law Firm is investigating potential securities claims on behalf of shareholders.
Quanterix Corporation (NASDAQ: QTRX) announced that its previously issued financial statements should no longer be relied upon, causing its stock price to drop 18.3%. The Rosen Law Firm is investigating potential securities claims on behalf of shareholders.
Quanterix Corporation (NASDAQ: QTRX) announced that its previously issued financial statements should no longer be relied upon, causing its stock price to drop 18.3%. The Rosen Law Firm is investigating potential securities claims on behalf of shareholders.
